2022 World Conference on Lung Cancer (ePosters)-EP08.02-012. Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea

EP08.02-012. Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea

Back to course

Pdf Summary

This study aimed to assess the effectiveness and safety of lorlatinib, a next-generation ALK tyrosine kinase inhibitor, in the treatment of ALK-positive non-small cell lung cancer (NSCLC) patients who had previously been treated with ALK tyrosine kinase inhibitors (TKIs). The study analyzed real-world data from patients in Korea.<br /><br />The study included 89 patients with advanced NSCLC who had undergone FISH and/or IHC testing for ALK and had previously received at least one ALK TKI. The patients were treated with lorlatinib at a dosage of 100mg once daily. The median age of the patients was 53, and 42.7% were male. The majority of patients (65.2%) were never smokers.<br /><br />The results showed that lorlatinib had a median progression-free survival of 7.92 months and a median overall survival of 30.1 months. The objective response rate was 37.1%, with a median duration of response of 6.9 months. Intracranial objective response rate was 31.0%.<br /><br />Adverse events related to treatment were reported, including hypercholesterolemia, limb edema, and AST/ALT elevation. Some patients also experienced adverse events such as psychosis and cognitive/mood effects, although these were less common.<br /><br />Overall, the study concluded that the real-world efficacy of lorlatinib in ALK-positive NSCLC patients who had previously received ALK TKIs was consistent with previous clinical trials. The study also highlighted the importance of considering the patient's treatment history and response to prior ALK inhibitors when determining the efficacy of subsequent lorlatinib treatment. Safety signals regarding psychosis were observed, indicating the need for caution when using lorlatinib.<br /><br />In summary, this real-world study in Korea demonstrated that lorlatinib is an effective treatment option for ALK-positive NSCLC patients who have become resistant to previous ALK TKIs. Further research and monitoring of safety signals is recommended to optimize the use of lorlatinib in this patient population.

Asset Subtitle

Beung-chul AHN

Meta Tag

Speaker Beung-chul AHN

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

lorlatinib

ALK-positive non-small cell lung cancer

tyrosine kinase inhibitor

real-world data

Korea

progression-free survival

overall survival

objective response rate

adverse events

treatment history